Evaluation of clinical efficacy and safety of tobramycin/dexamethasone ophthalmic suspension 0.3/0.05 compared to azithromycin ophthalmic solution 1 in the treatment of moderate to severe acute blepharitis/blepharoconjunctivitis

Current Medical Research and Opinion

Volumn 27, Issue 1, 2011, Pages 171-178

  Torkildsen, Gail L ^a   Cockrum, Paul ^b   Meier, Edward ^c   Hammonds, William M ^d   Silverstein, Bruce ^e   Silverstein, Steven ^f  

^a Andover Eye Associates   (United States)

^b ALCON RESEARCH LTD   (United States)

^c Eye Care Associates of Greater Cincinnati Inc   (United States)

^d Charlotte Eye Ear Nose and Throat Associates ^*  (United States)

^e Shasta Eye Medical Group Inc   (United States)

^f Silverstein Eye Centers   (United States)

Author keywords

Anti infective; Anti inflammatory; Clinical trial; Dexamethasone; Ophthalmic; Tobramycin

Indexed keywords

AZITHROMYCIN; DEXAMETHASONE PLUS TOBRAMYCIN; EYE DROPS;

ADULT; AGED; ARTICLE; BLEPHARITIS; BLURRED VISION; BURNING SENSATION; CHALAZION; CLINICAL TRIAL; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; EPIPHORA; FEMALE; HUMAN; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OCULAR PRURITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SUSPENSION; SYMPTOM; TREATMENT DURATION;

ADULT; AGED; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; AZITHROMYCIN; BLEPHARITIS; CONJUNCTIVITIS, BACTERIAL; DEXAMETHASONE; DRUG COMBINATIONS; FEMALE; HUMANS; INSTILLATION, DRUG; MALE; MIDDLE AGED; OPHTHALMIC SOLUTIONS; OSMOLAR CONCENTRATION; TOBRAMYCIN; TREATMENT OUTCOME; VALIDATION STUDIES AS TOPIC;

EID: 78650368333     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2010.539603     Document Type: Article

References (35)

1. Lemp MA, Nichols KK. Blepharitis in the United States 2009: a survey-based perspective on prevalence and treatment. Ocul Surf 2009;7(2 Suppl.):S1-S14
2. Jackson WB. Blepharitis: current strategies for diagnosis and management. Can J Ophthalmol 2008;43:170-9
3. Thygeson P. Etiology and treatment of blepharitis. A study in military personnel. Arch Ophthalmol 1946;36:445-57
4. Dougherty JM, McCulley JP. Comparative bacteriology of chronic blepharitis. Br J Ophthalmol 1984;68:524-8
5. Groden LR, Murphy B, Rodnite J, et al. Lid flora in blepharitis. Cornea 1991;10:50-3
6. McCulley JP, Dougherty JM. Bacterial aspects of chronic blepharitis. Trans Ophthalmol Soc UK 1986;105(Pt 3):314-8
7. Dougherty JM, McCulley JP. Bacterial lipases and chronic blepharitis. Invest Ophthalmol Vis Sci 1986;27:486-91
8. Novick RP. Interrupters on the bacterial party line. Nat Chem Biol 2005; 1:321-2
9. Wright 3rd JS, Jin R, Novick RP. Transient interference with staphylococcal quorum sensing blocks abscess formation. Proc Natl Acad Sci USA. 2005;102:1691-6
10. Abelson MB, Workman A, Taylor A. Eavesdropping in blepharitis: Once the bacteria start talking, the news they share may turn out to be bad. Rev Ophthalmol 2007;14(10):92-6
11. McCulley JP. Blepharoconjunctivitis. Int Ophthalmol Clin 1984;24:65-77
12. McCulley JP, Dougherty JM, Deneau DG. Classification of chronic blepharitis. Ophthalmology 1982;89:1173-80
13. Smith RE, Flowers Jr. CW Chronic blepharitis: a review. CLAO J 1995; 21:200-7
14. Mathers WD, Choi D. Cluster analysis of patients with ocular surface disease, blepharitis, and dry eye. Arch Ophthalmol 2004;122:1700-4
15. InSite Vision. Comparative study of Azasite Plus compared to Azasite alone and dexamethasone alone to treat subjects with blepharoconjunctivitis. Bethesda (MD): National Library of Medicine (US). Available at: http://clinical trials.gov/ct2/show/NCT00578955 [Last accessed 29 September 2010]
16. Ora, Inc. A single-center, double-masked, randomized, vehicle controlled study to evaluate the safety and efficacy of testosterone 0.03% ophthalmic solution compared to vehicle for the treatment of meibomian gland dysfunction. Bethesda (MD): National Library of Medicine (US). Available at: http:// clinicaltrials.gov/ct2/show/NCT00755183 [Last accessed 29 September 2010]
17. Huber-Spitzy V, Baumgartner I, Bö hler-Sommeregger K, et al. Blepharitis - a diagnostic and therapeutic challenge. A report on 407 consecutive cases. Graefes Arch Clin Exp Ophthalmol 1991;229:224-7
18. Denton P, Barequet IS, and O'Brien TP. Therapy of infectious blepharitis. Ophthalmology 1999;12:9-14
19. Seal DV, McGill JI, Jacobs P, et al. Microbial and immunological investigations of chronic non-ulcerative blepharitis and meibomianitis. Br J Ophthalmol 1985;69:604-11
20. Gilbard JP. Dry eye and blepharitis: approaching the patient with chronic eye irritation. Geriatrics 2009;64:22-6
21. John T, Shah AA. Use of azithromycin ophthalmic solution in the treatment of chronic mixed anterior blepharitis. Ann Ophthalmol (Skokie) 2008;40: 68-74
22. Haque RM, Torkildsen GL, Brubaker K, et al. Multicenter open-label study evaluating the efficacy of azithromycin ophthalmic solution 1% on the signs and symptoms of subjects with blepharitis. Cornea 2010;29: 871-7
23. Luchs J. Efficacy of topical azithromycin ophthalmic solution 1% in the treatment of posterior blepharitis. Adv Ther 2008;25:858-70
24. Inspire Pharmaceuticals. Inspire Announces Results From AZASITE(R) Phase 2 Blepharitis Trials And Plans To Continue Clinical Development In Anterior And Posterior Blepharitis. Medical News Today. March 17, 2010. Available at: http://www.medicalnewstoday.com/articles/182501.php. [Accessed November 3, 2010]
25. Inspire Pharmaceuticals. The effects of azithromycin ophthalmic solution, 1% versus placebo in subjects with blepharitis during a four-week treatment period. Bethesda (MD): National Library of Medicine (US), 2009. Available at: http://clinicaltrials.gov/ct2/show/NCT00894530 [Last accessed 3 November 2010]
26. Inspire Pharmaceuticals. The effects of azithromycin ophthalmic solution, 1% versus placebo in subjects with blepharitis during a two-week treatment period. Bethesda (MD): National Library of Medicine (US), 2010. Available at: http://clinicaltrials.gov/ct2/show/NCT00892970 [Last accessed 3 November 2010]
27. Weijtens O, Schoemaker RC, Romijn FP, et al. Intraocular penetration and systemic absorption after topical application of dexamethasone disodium phosphate. Ophthalmology 2002;109:1887-91.28.
28. Pelletier JS, Stewart K, Trattler W, et al. A combination povidone-iodine 0.4%/dexamethasone 0.1% ophthalmic suspension in the treatment of ade-noviral conjunctivitis. Adv Ther 2009;26:776-83
29. Awan MA, Agarwal PK, Watson DG, et al. Penetration of topical and sub-conjunctival corticosteroids into human aqueous humour and its therapeutic significance. Br J Ophthalmol 2009;93:708-13
30. Holland EJ, Bartlett JD, Paterno MR, et al. Effects of loteprednol/tobramycin versus dexamethasone/tobramycin on intraocular pressure in healthy volunteers. Cornea 2008;27:50-5
31. Tamaoki J, Kadota J, Takizawa H. Clinical implications of the immunomod-ulatory effects of macrolides. Am J Med 2004;117(Suppl. 9A):5S-11S
32. Zalewska-Kaszubska J, Gorska D. Anti-inflammatory capabilities of macro-lides. Pharmacol Res 2001;44:451-4
33. Ianaro A, Ialenti A, Maffia P, et al. Anti-inflammatory activity of macrolide antibiotics. J Pharmacol Exp Ther 2000;292:156-63
34. Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids - new mechanisms for old drugs. N Engl J Med 2005;353:1711-23
35. Cheung PS, Si EC, Hosseini K. Anti-inflammatory activity of azithromycin as measured by its NF-kappaB, inhibitory activity. Ocul Immunol Inflamm 2010; 18:32-7